RxDoctor Payments Data

Peter Chi, MD

Family Medicine · Temple City, CANPI 1023090867

Payments from drug & device makers

$16,191in general payments, 2019–2025

Across 419 payments — averaging $38.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Medtronic$1K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$1K
  • plus $8K from 39 others

What the payments were for

  • Travel & lodging$9836%
  • Food & beverage$15,10193%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,191 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$846,576
Medicare patients
528
Services billed
8,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin327$283,000
EliquisApixaban311$166,129
FarxigaDapagliflozin Propanediol135$126,632
RybelsusSemaglutide60$100,277
OzempicSemaglutide84$91,248
XareltoRivaroxaban131$83,290
MounjaroTirzepatide76$77,766
JanuviaSitagliptin Phosphate87$56,731
ProliaDenosumab20$33,693
UbrelvyUbrogepant14$32,422
KerendiaFinerenone26$28,660
Repatha SureclickEvolocumab24$21,981
VascepaIcosapent Ethyl49$21,803
JanumetSitagliptin Phos/Metformin Hcl22$20,932
RexultiBrexpiprazole26$19,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$1,024$299,746342 claims
Novo NordiskRybelsus, Ozempic$955$191,525144 claims
PfizerEliquis, Lyrica$86$182,066327 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,410$139,061149 claims
Johnson & JohnsonXarelto, Invokana$1,240$97,077146 claims
Lilly USA, LLCMounjaro$500$77,76676 claims
AbbVieUbrelvy, Linzess$1,337$41,64729 claims
GSKTrelegy Ellipta, Breo Ellipta$744$33,84758 claims
AmgenProlia$1,648$33,69320 claims
BayerKerendia$777$28,66026 claims
Otsuka America Pharmaceutical, Inc.Rexulti$317$19,90926 claims
Smith+NephewSantyl$129$15,04315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Temple City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →